Abstract
Increased levels of low-density lipoproteins are well-established risk factors of endothelial dysfunction and the metabolic syndrome. In this study, we evaluated the effect of native low-density lipoprotein (nLDL) and oxidized LDL (oxLDL) on the expression of genes of the renin-angiotensin system (angiotensin-converting enzyme, ACE; angiotensin II type 1 receptor, AT1) and their receptors (low-density lipoprotein receptor: LDLR; lectin-like oxLDL receptor: LOX-1; toll-like receptor 4: TLR4) in primary cultures of human umbilical vein endothelial cells. ACE and AT1 expressions were significantly increased after stimulation with nLDL and oxLDL. OxLDL receptor LOX-1 showed a maximum induction after 7 hours. Increased LOX-1 protein expression in response to oxLDL could be blocked by a LOX-1-specific antibody. TLR4 expression was increased by nLDL and oxLDL as well. We conclude that LDL and oxLDL can activate the renin-angiotensin system and their receptors LDLR, LOX-1, and TLR4 in human endothelial cells. These data suggest a novel link between hypercholesterolemia and hypertension in patients with the metabolic syndrome.
Key words
endothelial cells - low-density lipoprotein - oxLDL receptor - renin-angiotensin system
References
-
1
Bonora E.
The metabolic syndrome and cardiovascular disease.
Ann Med.
2006;
38
64-80
-
2
Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD.
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study.
Lancet.
2006;
368
919-928
-
3
Nickenig G.
Should angiotensin II receptor blockers and statins be combined?.
Circulation.
2004;
110
1013-1020
-
4
Lusis AJ.
Atherosclerosis.
Nature.
2000;
407
233-241
-
5
Kjeldsen SE, Julius S.
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Am Heart J.
2004;
148
747-754
-
6
Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K.
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).
Circulation.
2001;
103
919-925
-
7
Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM.
Inhibition of early atherogenesis by losartan in monkeys with diet- induced hypercholesterolemia.
Circulation.
2000;
101
1586-1593
-
8
Ferrario CM, Smith R, Levy P, Strawn W.
The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis.
Am J Med Sci.
2002;
323
17-24
-
9
Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H.
Upregulation of vascular angiotensin II receptor gene expression by low- density lipoprotein in vascular smooth muscle cells.
Circulation.
1997;
95
473-478
-
10
Nickenig G, Sachinidis A, Seewald S, Bohm M, Vetter H.
Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression.
J Hypertens Suppl.
1997;
15
S27-S30
-
11
Kong WJ, Liu J, Jiang JD.
Human low-density lipoprotein receptor gene and its regulation.
J Mol Med.
2006;
84
29-36
-
12
Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T.
An endothelial receptor for oxidized low-density lipoprotein.
Nature.
1997;
386
73-77
-
13
Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M.
Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL.
Circulation.
2001;
104
3103-3108
-
14
Faure E, Equils O, Sieling PA, Thomas L, Zhang FX, Kirschning CJ, Polentarutti N, Muzio M, Arditi M.
Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells.
J Biol Chem.
2000;
275
11058-11063
-
15
Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H.
Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy.
Circulation.
2001;
104
1767-1772
-
16
Muller G, Catar RA, Niemann B, Barton M, Knels L, Wendel M, Morawietz H.
Upregulation of endothelin receptor B in human endothelial cells by low-density lipoproteins.
Exp Biol Med (Maywood).
2006;
231
766-771
-
17
Niemann B, Rohrbach S, Catar RA, Muller G, Barton M, Morawietz H.
Native and oxidized low-density lipoproteins stimulate endothelin-converting enzyme-1 expression in human endothelial cells.
Biochem Biophys Res Commun.
2005;
334
747-753
-
18
Schubert A, Cattaruzza M, Hecker M, Darmer D, Holtz J, Morawietz H.
Shear stress-dependent regulation of the human β-tubulin folding cofactor D gene.
Circ Res.
2000;
87
1188-1194
-
19
Li D, Singh RM, Liu L, Chen H, Singh BM, Kazzaz N, Mehta JL.
Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells.
Cardiovasc Res.
2003;
57
238-243
-
20
Li D, Saldeen T, Romeo F, Mehta JL.
Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells: the potential role of transcription factor NF-kappaB.
Circulation.
2000;
102
1970-1976
-
21
Ko Y, Glodny B, Stier S, Totzke G, Nickenig G, Dusing R, Sachinidis A, Vetter H.
Angiotensin type-1 (AT1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells.
Biochem Pharmacol.
1997;
53
417-421
-
22
Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR, Sawamura T, Holtz J.
Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein.
Circulation.
1999;
100
899-902
-
23
Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL.
Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II type 1 receptor activation.
Circ Res.
1999;
84
1043-1049
-
24
Muller G, Goettsch C, Morawietz H.
Oxidative stress and endothelial dysfunction.
Hamostaseologie.
2007;
27
5-12
-
25
Dhaliwal BS, Steinbrecher UP.
Scavenger receptors and oxidized low density lipoproteins.
Clin Chim Acta.
1999;
286
191-205
-
26
Chen M, Masaki T, Sawamura T.
LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis.
Pharmacol Ther.
2002;
95
89-100
-
27
Mehta JL, Li DY.
Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells.
Biochem Biophys Res Commun.
1998;
248
511-514
-
28
Dimmeler S, Haendeler J, Galle J, Zeiher AM.
Oxidized low-density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases. A mechanistic clue to the ‘response to injury’ hypothesis.
Circulation.
1997;
95
1760-1763
-
29
Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M.
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E.
Proc Natl Acad Sci USA.
2004;
101
10679-10684
-
30
Yang QW, Mou L, Lv FL, Wang JZ, Wang L, Zhou HJ, Gao D.
Role of Toll-like receptor 4/NF-kappaB pathway in monocyte-endothelial adhesion induced by low shear stress and ox-LDL.
Biorheology.
2005;
42
225-236
-
31
Bornstein SR, Schumann RR, Rettori V, MacCann SM, Zacharowski K.
Toll-like receptor 2 and Toll-like receptor 4 expression in human adrenals.
Horm Metab Res.
2004;
36
470-473
-
32
Bornstein SR, Morawietz H.
Toll-like receptors, endocrine stress response, and arteriosclerosis.
Arterioscler Thromb Vasc Biol.
2005;
25
e135
-
33
Warnholtz A, Nickenig G, Schulz E, Macharzina R, Brasen JH, Skatchkov M, Heitzer T, Stasch JP, Griendling KK, Harrison DG, Bohm M, Meinertz T, Munzel T.
Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin- angiotensin system.
Circulation.
1999;
99
2027-2033
-
34
Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhovel F, Bohm M.
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
Circulation.
1999;
100
2131-2134
-
35
Schjoedt KJ, Jacobsen P, Rossing K, Boomsma F, Parving HH.
Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Horm Metab Res.
2005;
37
((Suppl 1))
4-8
Correspondence
H. MorawietzPhD
University of Technology Dresden
Carl Gustav Carus Medical School
Medical Clinic and Policlinic III
Department of Vascular Endothelium and Microcirculation
Fetscherstrasse 74
01307 Dresden
Germany
Phone: +49/351/458 66 25
Fax: +49/351/458 63 54
Email: Henning.Morawietz@tu-dresden.de